Advertisement
U.S. markets closed

Braxia Scientific Corp. (BRAXF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0073+0.0001 (+1.39%)
At close: 03:09PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0072
Open0.0075
BidN/A x N/A
AskN/A x N/A
Day's Range0.0070 - 0.0075
52 Week Range0.0040 - 0.0200
Volume138,800
Avg. Volume115,875
Market Cap2.07M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BRAXF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BRAXIA SCIENTIFIC CORP
    Analyst Report: KeyCorpWith assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
    Rating
    Fair Value
    Economic Moat
    6 months agoMorningstar
View more
  • Newsfile

    Braxia Scientific Reports Q3 2024 Financial Results

    Toronto, Ontario--(Newsfile Corp. - February 29, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and nine months ended December 31, 2023. Complete financial statements along with rela

  • Newsfile

    Braxia Scientific Reports Mandatory Conversion of Debentures

    Toronto, Ontario--(Newsfile Corp. - January 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the mandatory conversion of $2,935,714 in convertible debentures, which matured on December 31, 2023, into 19,571,411 common shares at a conversion price of $0.15 per common share.About

  • Newsfile

    Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update

    Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months ended September 30, 2023. Complete financial statements along with relat